ESSEX BIO-TECH Issues Profit Warning, Anticipates Approximately 30% Drop in Interim Profit

Stock News
07/17

The company has announced that for the six-month period ending June 30, 2026, it expects both revenue and profit to decline compared to the same period in 2025.

Revenue is projected to decrease by approximately 10%, and profit is anticipated to fall by around 30% relative to the prior year's figures of about HK$877 million in revenue and HK$163 million in profit.

The primary reason cited for this expected downturn is an increase in the value-added tax borne by the group following the implementation of a new VAT law in China.

Despite these challenges, the company states that it maintains robust cash flow and a solid financial position sufficient to meet its operational requirements.

As of June 30, 2026, the group's cash and cash equivalents stood at approximately HK$807 million.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10